Clinical Trial Update: Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating jaktinib for patients with myelofibrosis intolerant to ruxolitinib has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Jaktinib (jaktinib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF) | Phase 2 | Status: COMPLETED